Reverse mergers say hey as biotechs trade low, hunt for alternatives and launch few IPOs
The reverse merger announced Wednesday morning between Magenta Therapeutics and privately-held Dianthus Therapeutics, which will take over the Nasdaq spot and push forward its complement …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
